Aquestive Therapeutics Quarterly Cash Flow Statement
NASDAQ: AQSTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Aquestive Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Aquestive Therapeutics generated -$9.4 million of operating cash flow and spent $212,000 on capital expenditures. That left free cash flow of -$9.7 million, a free-cash-flow margin of -69.9% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Aquestive Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -22.86M | -8.06M | -31.86M | -15.45M | -13.55M | -22.93M | -17.05M | -11.51M | -2.75M | -12.83M | -8.11M | -2.04M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | -259.00% | — | — |
| Depreciation & Amortization | 136.00K | 113.00K | 130.00K | 139.00K | 140.00K | 139.00K | 147.00K | 159.00K | 205.00K | 207.00K | 467.00K | 264.00K |
| Stock-Based Compensation | 2.90M | 2.32M | 1.38M | 2.78M | 1.88M | 1.59M | 2.40M | 1.58M | 1.54M | 1.58M | 940.00K | 774.00K |
| Change in Working Capital | -3.32M | -9.59M | 14.04M | -3.00M | 319.00K | -2.22M | 4.37M | -4.17M | -8.49M | -175.00K | -2.05M | -2.61M |
| Operating Cash Flow | -9.44M | -14.81M | -8.47M | -12.65M | -7.91M | -23.40M | -6.49M | -11.88M | -7.01M | -10.38M | -4.94M | -2.35M |
| Capital Expenditures | -212.00K | -52.00K | -85.00K | -235.00K | -107.00K | -135.00K | -15.00K | -80.00K | -35.00K | -29.00K | -16.00K | -151.00K |
| Investing Cash Flow | -212.00K | -52.00K | -85.00K | -235.00K | -107.00K | -135.00K | -15.00K | -80.00K | -35.00K | -29.00K | -16.00K | -151.00K |
| Debt Repaid | -44.99M | -8.00K | — | — | 6.00K | -6.00K | — | — | — | — | — | — |
| Financing Cash Flow | -2.59M | 4.42M | 660.00K | 81.41M | -100.00K | 20.65M | 157.00K | -17.00K | 1.71M | 81.74M | 3.91M | 4.98M |
| Net Change in Cash | -12.24M | -10.44M | -7.89M | 68.53M | -8.12M | -2.89M | -6.35M | -11.98M | -5.33M | 71.33M | -1.04M | 2.48M |
| Free Cash Flow | -9.65M | -14.86M | -8.55M | -12.88M | -8.02M | -23.54M | -6.50M | -11.96M | -7.04M | -10.41M | -4.96M | -2.50M |
This table shows 12 quarterly periods of Aquestive Therapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow AQST's reporting calendar. What is a cash flow statement?